Experimental CAR T-Cell therapy targets rare B-Cell cancers
Disease control
Terminated
This phase 2 study tested a treatment called brexucabtagene autoleucel, a CAR T-cell therapy made from a patient's own immune cells, for four rare B-cell cancers: Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The trial enrolled …
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC